No Data
Guangdong Biolight Meditech Co., Ltd. (SZSE:300246) Held Back By Insufficient Growth Even After Shares Climb 33%
Southwest Securities: The stable trend of hemodialysis treatment rates is expected to improve the concentration of domestic consumables through centralized procurement.
The time for domestic substitution of equipment is right; under the centralized procurement policy, leading enterprises with strong supply capabilities have a high selection rate, and the concentration of the Industry is expected to increase.
Guangdong Biolight Meditech (300246.SZ): Cumulatively repurchased 1.1228% of shares.
Gelonghui, February 5: Guangdong Biolight Meditech (300246.SZ) announced that as of January 31, 2025, the company had cumulatively repurchased 2,970,600 shares of the company through a dedicated securities account for share repurchase via centralized bidding, accounting for 1.1228% of the company's total share capital; the highest Fill Price was 7.07 RMB/share, the lowest Fill Price was 6.31 RMB/share, and the total amount paid was 20,007,148.50 RMB (excluding stamp duty, trading commission, and other transaction costs). This share repurchase by the company complies with the relevant laws and regulations.
Paulette: 2024 Annual Results Forecast
Guangdong Biolight Meditech (300246.SZ) holding subsidiary Suzhou Junkang received a government subsidy of 60.43 million yuan.
Guangdong Biolight Meditech (300246.SZ) announced that the company's controlling subsidiary, Suzhou Juncang Medical Technology Co., Ltd. (referred to as "Suz...
Guangdong Biolight Meditech (300246.SZ): In the first half of the year, the revenue from the health monitoring sector was 0.133 billion yuan, accounting for approximately 25% of the total revenue.
Gelonghui November 19th | Guangdong Biolight Meditech (300246.SZ) stated in investor relations that, as an example in the first half of 2024, the company's health monitoring sector sales revenue was 133.3011 million yuan, accounting for approximately 25% of the revenue; blood purification sector sales revenue was 398.564 million yuan, accounting for approximately 74% of the revenue.
The Market Doesn't Like What It Sees From Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Revenues Yet As Shares Tumble 26%